CRISPR activation of endogenous PKD1 increases polycystin-1 levels and suppresses cellular features of ADPKD
- 1University of Kansas Medical Center
Abstract
Most cases of autosomal dominant polycystic kidney disease (ADPKD) are caused by mutations in PKD1, which reduce polycystin-1 (PC1) levels below a critical functional threshold. Normalizing PC1 dosage mitigates disease progression; therefore, we sought to develop a CRISPR activation (CRISPRa) strategy to transcriptionally upregulate endogenous PKD1. We systematically screened multiple single-guide RNAs using an EGFP-reporter platform and identified potent candidates targeting the proximal PKD1 promoter in mouse and human cell models. Our results demonstrate that CRISPRa effectively increased endogenous Pkd1 mRNA in the mouse collecting duct-derived Pkd1RC/-cell model and in the primary renal epithelial cells from PKD mice. In Pkd1RC/- cells, CRISPRa of Pkd1 increased PC1 protein levels and significantly reduced cell proliferation and in vitro cyst formation in 3D cultures. Mechanistically, Pkd1 activation improved mitochondrial membrane potential, reduced dependency on aerobic glycolysis, and corrected signaling pathways involved in cystogenesis, specifically reducing intracellular cAMP, cMyc, pCreb, and pErk levels, while increasing pYap1 levels. We confirmed the translational potential of this platform by successfully activating PKD1 in primary renal epithelial cells from human kidneys. We observed a heterogeneous response across both normal and ADPKD patient-derived donor lines, with significant upregulation achieved in two of the tested cell preparations. These findings provide a compelling proof-of-concept that CRISPRa-mediated gene augmentation can increase PC1 levels, establishing a foundation for promising gene therapies aimed at successfully suppressing the pathogenic features of ADPKD.
Versions
Related
- Mechanisms of stress-induced cellular HSP72 release: implications for exercise-induced increases in extracellular HSP72
- Peptidoglycan Suppresses Melanoma Growth in a Murine Model with Local Immune Activation
- Endogenous Retrovirus-Targeted Immunotherapy for Non-Small Cell Lung Cancer Supported by Cellular HERV-K Expression, Dependency and Efficacy of ERV Therapy in a Murine Model
- A circRNA-derived IRES-like element enables programmable translational activation of the endogenous chaperone HSP90
- NDFIP2 Suppresses Colorectal Cancer Metastasis Through DDX3X‐Dependent R‐Loop Remodeling and GNG13 Transcriptional Activation
BibTeX
@misc{chakraborty2026crispr,
title = {{CRISPR activation of endogenous PKD1 increases polycystin-1 levels and suppresses cellular features of ADPKD}},
author = {A. Chakraborty and M. M. Varghese and D. P. Wallace and C. J. Ward and A. S. Yu},
howpublished = {bioRxiv},
year = {2026},
month = may,
doi = {10.64898/2026.05.23.727418},
url = {https://www.biorxiv.org/content/10.64898/2026.05.23.727418v2},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - CRISPR activation of endogenous PKD1 increases polycystin-1 levels and suppresses cellular features of ADPKD
AU - A. Chakraborty
AU - M. M. Varghese
AU - D. P. Wallace
AU - C. J. Ward
AU - A. S. Yu
PY - 2026
DA - 2026/05/23
PB - bioRxiv
DO - 10.64898/2026.05.23.727418
UR - https://www.biorxiv.org/content/10.64898/2026.05.23.727418v2
AB - Most cases of autosomal dominant polycystic kidney disease (ADPKD) are caused by mutations in PKD1, which reduce polycystin-1 (PC1) levels below a critical functional threshold. Normalizing PC1 dosage mitigates disease progression; therefore, we sought to develop a CRISPR activation (CRISPRa) strategy to transcriptionally upregulate endogenous PKD1. We systematically screened multiple single-guide RNAs using an EGFP-reporter platform and identified potent candidates targeting the proximal PKD1 promoter in mouse and human cell models. Our results demonstrate that CRISPRa effectively increased endogenous Pkd1 mRNA in the mouse collecting duct-derived Pkd1RC/-cell model and in the primary renal epithelial cells from PKD mice. In Pkd1RC/- cells, CRISPRa of Pkd1 increased PC1 protein levels and significantly reduced cell proliferation and in vitro cyst formation in 3D cultures. Mechanistically, Pkd1 activation improved mitochondrial membrane potential, reduced dependency on aerobic glycolysis, and corrected signaling pathways involved in cystogenesis, specifically reducing intracellular cAMP, cMyc, pCreb, and pErk levels, while increasing pYap1 levels. We confirmed the translational potential of this platform by successfully activating PKD1 in primary renal epithelial cells from human kidneys. We observed a heterogeneous response across both normal and ADPKD patient-derived donor lines, with significant upregulation achieved in two of the tested cell preparations. These findings provide a compelling proof-of-concept that CRISPRa-mediated gene augmentation can increase PC1 levels, establishing a foundation for promising gene therapies aimed at successfully suppressing the pathogenic features of ADPKD.
ER -